Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal D. Shore(Carolina Urologic Research Center), Bertrand Tombal(Cliniques Universitaires Saint-Luc), Daniel J. George(Duke University), Michael S. Cookson(University of Oklahoma Health Sciences Center), Fred Saad(Centre Hospitalier de l’Université de Montréal), Ronald Tutrone(The University of Texas System), David Friedrich Van Veenhuyzen(The University of Texas System), Vicky Kang(The University of Texas System), Alberto Bossi(Institut Gustave Roussy), Daniel R. Saltzstein(Urology San Antonio), Xiaolin Fan(Novartis (United States)), Bryan Selby(The University of Texas System), Hideyuki Akaza(Tokyo University of Information Sciences), Jackie Walling(Heidelberg University)
Cited by 442
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k